InMode (INMD) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was $92.1M, broadly in line with Q3 2025; FY 2026 guidance was reaffirmed.

• U.S. and international capital equipment revenue was relatively stable QoQ, with stabilization expected through year-end.

• The global RF-based aesthetics and wellness platform spans 104 countries, 12 product families and 33,400 installed units; U.S. installations totaled 14,000, supported by 298 direct sales reps.

Financial highlights

• Q3 GAAP revenue was $92.1M vs. $93.2M; nine-month revenue was $269.7M vs. $266.6M.

• Q3 GAAP net income was $18.9M and diluted EPS was $0.32; non-GAAP net income was $21.9M and diluted EPS was $0.37.

• Nine-month GAAP net income was $47.5M vs. $66.8M; non-GAAP net income was $58.6M vs. $76.1M.

Outlook and guidance

• FY 2026 guidance reaffirmed: revenue of $365M–$375M, non-GAAP gross margin of 74%–76%, non-GAAP operating income of $68M–$73M and non-GAAP diluted EPS of $1.29–$1.34.

• Guidance reflects current estimates; forward-looking outcomes are subject to risks and uncertainties.

• Pipeline aims to expand medical offerings and adapt proprietary RF technologies for plastic surgery, OB/GYN, ENT and ophthalmology.